Ballicules.com

Bicalutamide

CASODEX

What it isNonsteroidal androgen-receptor antagonist; prostate cancer.

Why this oneIts main clinical niche is suppressing the testosterone flare when a GnRH agonist is initiated.

What limits itGynecomastia and breast tenderness are characteristic; hepatotoxicity requires liver monitoring.

FDA-approved for

FDA label

FDA dosingPopulationStartTargetMax
Advanced prostate cancer (with LHRH analog)Adult males50 mg QD50 mg QD50 mg QD

Renal No adjustment needed

Hepatic No adjustment needed (incl. severe impairment, despite ~76% increase in half-life)

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Contraindicated — can cause fetal harm; not indicated in females

Lactation Not indicated in females; no human milk data (detected in rat milk)

NO BOXED WARNINGS

Principal riskGynecomastia; hepatotoxicity needing liver monitoring

Cost, est. cash$10–$1,000/month

Generic entry2009

Classes and tags

Clinical profile

Therapeutic safety burden2 / 4
Overdose danger2 / 4
Weight-gain liability0 / 4
Sedation liability0 / 4
QT / Torsades2 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk3 / 4

Legacy pregnancy categoryMultiple / indication-, trimester- or formulation-dependent

Defining liabilityThrombotic, metabolic, hepatic, skeletal or reproductive toxicity varies by hormonal target.

Mechanism of action: Bicalutamide ballicule

Bicalutamide ballicule: receptor binding, kinetics and half-life diagram

Open Bicalutamide in the interactive console ↗

Memory aids: mascots and interaction avatars

Bicalutamide CASODEX mascot mnemonic cartoon
“Cassette deck/Bike colluder”

Open Bicalutamide in the interactive console ↗